Floatz logo

163 assets in Urothelial Carcinoma

Therapeutic assets addressing Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Incb 086550
Urothelial Carcinoma
Incyte CorporationP2C (36)
Sasanlimab
Urothelial Carcinoma
PfizerP1D (31)
13C-Fructose
Urothelial Carcinoma
University of Texas Southwestern Medical CenterN/AD (30)
68ga-nota-nectin-4 antibody fragment
Urothelial Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyN/AD (30)
Acetic-1-13C Acid
Urothelial Carcinoma
University of Texas Southwestern Medical CenterN/AD (30)
Batiraxcept
Urothelial Carcinoma
University of OklahomaP1D (30)
Glucose, Anhydrous
Urothelial Carcinoma
University of Texas Southwestern Medical CenterN/AD (30)
Glutamine
Urothelial Carcinoma
University of Texas Southwestern Medical CenterN/AD (30)
Lactate
Urothelial Carcinoma
University of Texas Southwestern Medical CenterN/AD (30)
Ntx-301
Urothelial Carcinoma
Xennials Therapeutics Australia Pty LtdP1/2NR ()
TJ271
Urothelial Carcinoma
TJ Biopharma Co., Ltd.P2NR ()
xl495
Urothelial Carcinoma
ExelixisP1NR ()
Showing 151 to 163 of 163 assets
PreviousPage 4 of 4Next